Rhinocerebral mucormycosis: evolution of the disease and treatment options

Laryngoscope. 1997 Jul;107(7):855-62. doi: 10.1097/00005537-199707000-00004.

Abstract

Rhinocerebral mucormycosis is recognized as a potentially aggressive and commonly fatal fungal infection. The classic presentation is involvement of nasal mucosa with invasion of the paranasal sinuses and orbit. Mucormycosis is most commonly seen in association with diabetic ketoacidosis, but disease demographics have changed with the onset of AIDS and the advent of powerful immunosuppressive drugs. Treatment includes aggressive debridement, systemic antifungal therapy, and control of underlying comorbid factors. Although surgical intervention remains essential, advances in medical therapy have permitted a more limited surgical approach to minimize functional loss without compromising survival. We present the UCLA experience with rhinocerebral mucormycosis from 1955 to 1995, with emphasis on the evolution of disease presentation and alternative treatment options.

MeSH terms

  • AIDS-Related Opportunistic Infections / diagnosis
  • Adolescent
  • Adult
  • Aged
  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use
  • Brain Diseases / diagnosis
  • Brain Diseases / microbiology*
  • Brain Diseases / surgery
  • Child
  • Combined Modality Therapy
  • Debridement
  • Diabetic Ketoacidosis / complications
  • Female
  • Follow-Up Studies
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Mucormycosis / diagnosis*
  • Mucormycosis / surgery
  • Nasal Mucosa / microbiology
  • Nose Diseases / diagnosis
  • Nose Diseases / microbiology*
  • Nose Diseases / surgery
  • Opportunistic Infections / diagnosis
  • Orbital Diseases / diagnosis
  • Orbital Diseases / microbiology
  • Orbital Diseases / surgery
  • Paranasal Sinus Diseases / diagnosis
  • Paranasal Sinus Diseases / microbiology
  • Paranasal Sinus Diseases / surgery
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Immunosuppressive Agents
  • Amphotericin B